Wednesday, August 10, 2022

Administrators appointed to Leeds pharmaceutical company

James Clark and David Pike from Interpath Advisory have been appointed joint administrators to 4D Pharma plc.

Headquartered in Leeds and listed on both AIM and NASDAQ, the pharmaceutical company focusses on the development of Live Biotherapeutics, an innovative and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.

The company has six clinical programs underway, including therapeutic trials for conditions including cancer, asthma and Parkinson’s Disease.

The company has a number of subsidiaries which are currently not subject to an insolvency process, with facilities based in Scotland, Ireland, Spain, and the US.

The company had recently embarked on a fundraising exercise to help fuel the next stage of its growth. However, with significant uncertainty currently affecting the global capital markets, the company was ultimately unable to progress the fundraise sufficiently quickly to deliver the required funding into the business.

Against this backdrop, and with the company requiring significant cash to fund day-to-day trading, the secured lender found it necessary to take action to protect its collateral, and subsequently sought the appointment of joint administrators.

James Clark, Managing Director at Interpath Advisory and joint administrator, said: “Since its inception, 4D Pharma has been at the forefront of innovation around the development and use of live biotherapeutic products, but unfortunately has been impacted by the growing uncertainty gripping the capital markets.

“Our intention is to try to stabilise the company in the immediate term whilst we assess options for the business. We would encourage any parties interested in acquiring the business to contact us at the earliest opportunity. At this stage, 4D Pharma plc’s subsidiaries remain outside of an insolvency process and continue to trade.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemichaving a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

Related news

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close